These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20346966)

  • 1. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.
    Paterson NE; Fedolak A; Olivier B; Hanania T; Ghavami A; Caldarone B
    Pharmacol Biochem Behav; 2010 Jun; 95(4):449-56. PubMed ID: 20346966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.
    Quisenberry AJ; Baker LE
    Psychopharmacology (Berl); 2015 Dec; 232(24):4411-9. PubMed ID: 26374456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effects of modafinil and d-amphetamine in male Sprague-Dawley rats trained to discriminate d-amphetamine.
    Quisenberry AJ; Prisinzano T; Baker LE
    Pharmacol Biochem Behav; 2013 Sep; 110():208-15. PubMed ID: 23880213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors.
    Schmitt KC; Reith ME
    PLoS One; 2011; 6(10):e25790. PubMed ID: 22043293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study.
    Wuo-Silva R; Fukushiro DF; Borçoi AR; Fernandes HA; Procópio-Souza R; Hollais AW; Santos R; Ribeiro LT; Corrêa JM; Talhati F; Saito LP; Aramini TC; Kameda SR; Bittencourt LR; Tufik S; Frussa-Filho R
    Addict Biol; 2011 Oct; 16(4):565-79. PubMed ID: 21790900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants.
    Dopheide MM; Morgan RE; Rodvelt KR; Schachtman TR; Miller DK
    Eur J Pharmacol; 2007 Jul; 568(1-3):112-23. PubMed ID: 17477916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction.
    Shuman T; Cai DJ; Sage JR; Anagnostaras SG
    Behav Brain Res; 2012 Dec; 235(2):105-12. PubMed ID: 22963989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.
    Loland CJ; Mereu M; Okunola OM; Cao J; Prisinzano TE; Mazier S; Kopajtic T; Shi L; Katz JL; Tanda G; Newman AH
    Biol Psychiatry; 2012 Sep; 72(5):405-13. PubMed ID: 22537794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic role in stimulant-induced wakefulness.
    Wisor JP; Nishino S; Sora I; Uhl GH; Mignot E; Edgar DM
    J Neurosci; 2001 Mar; 21(5):1787-94. PubMed ID: 11222668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil.
    Gold LH; Balster RL
    Psychopharmacology (Berl); 1996 Aug; 126(4):286-92. PubMed ID: 8878344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
    Zolkowska D; Jain R; Rothman RB; Partilla JS; Roth BL; Setola V; Prisinzano TE; Baumann MH
    J Pharmacol Exp Ther; 2009 May; 329(2):738-46. PubMed ID: 19197004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.
    Uguen M; Perrin D; Belliard S; Ligneau X; Beardsley PM; Lecomte JM; Schwartz JC
    Br J Pharmacol; 2013 Jun; 169(3):632-44. PubMed ID: 23472741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modafinil acquires reinforcing effects when combined with citalopram.
    Yepez JE; Juárez J
    Pharmacol Biochem Behav; 2022 Jun; 217():173407. PubMed ID: 35605783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.
    Avelar AJ; Cao J; Newman AH; Beckstead MJ
    Neuropharmacology; 2017 Sep; 123():410-419. PubMed ID: 28625719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats.
    Ishizuka T; Murakami M; Yamatodani A
    Eur J Pharmacol; 2008 Jan; 578(2-3):209-15. PubMed ID: 17920581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate.
    Lazenka MF; Negus SS
    Behav Pharmacol; 2017 Jun; 28(4):318-322. PubMed ID: 28125506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation.
    Federici M; Latagliata EC; Rizzo FR; Ledonne A; Gu HH; Romigi A; Nisticò R; Puglisi-Allegra S; Mercuri NB
    Neuroscience; 2013 Nov; 252():118-24. PubMed ID: 23933217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat.
    Edgar DM; Seidel WF
    J Pharmacol Exp Ther; 1997 Nov; 283(2):757-69. PubMed ID: 9353396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.